We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Puma Biotechnology Inc | NASDAQ:PBYI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.20% | 4.94 | 4.93 | 4.95 | 4.97 | 4.77 | 4.97 | 272,519 | 20:52:13 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
ADAGE CAPITAL PARTNERS GP, L.L.C. |
2. Issuer Name
and
Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
200 CLARENDON STREET, 52ND FLOOR, |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
BOSTON, MA 02116 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock, par value $0.0001 ("Common Stock") | 5/24/2017 | S | 50000 | D | $68.1291 (1) | 5636668 | I | See footnote (2) | ||
Common Stock | 5/24/2017 | S | 39115 | D | $69 | 5597553 | I | See footnote (2) | ||
Common Stock | 5/24/2017 | S | 53600 | D | $70.3077 (3) | 5543953 | I | See footnote (2) | ||
Common Stock | 5/24/2017 | S | 52300 | D | $72.2167 (4) | 5491653 | I | See footnote (2) | ||
Common Stock | 5/24/2017 | S | 175687 | D | $73.2885 (5) | 5315966 | I | See footnote (2) | ||
Common Stock | 5/24/2017 | S | 48865 | D | $74.4872 (6) | 5267101 | I | See footnote (2) | ||
Common Stock | 5/24/2017 | S | 116133 | D | $75 | 5150968 | I | See footnote (2) | ||
Common Stock | 5/25/2017 | S | 85526 | D | $76.9061 (7) | 5065442 | I | See footnote (2) | ||
Common Stock | 5/25/2017 | S | 232190 | D | $77.6149 (8) | 4833252 | I | See footnote (2) | ||
Common Stock | 5/25/2017 | S | 7248 | D | $78.2452 (9) | 4826004 | I | See footnote (2) | ||
Common Stock | 5/25/2017 | S | 75036 | D | $79.7026 (10) | 4750968 | I | See footnote (2) | ||
Common Stock | 5/26/2017 | S | 187847 | D | $76.7156 (11) | 4563121 | I | See footnote (2) | ||
Common Stock | 5/26/2017 | S | 111823 | D | $77.6639 (12) | 4451298 | I | See footnote (2) | ||
Common Stock | 5/26/2017 | S | 330 | D | $78.3545 (13) | 4450968 | I | See footnote (2) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
ADAGE CAPITAL PARTNERS GP, L.L.C.
200 CLARENDON STREET, 52ND FLOOR BOSTON, MA 02116 |
|
X |
|
|
|
Adage Capital Partners, L.P.
200 CLARENDON STREET, 52ND FLOOR BOSTON, MA 02116 |
|
X |
|
|
|
Adage Capital Advisors, L.L.C.
200 CLARENDON STREET 52ND FLOOR BOSTON, MA 02116 |
|
X |
|
|
|
Atchinson Robert
200 CLARENDON STREET 52ND FLOOR BOSTON, MA 02116 |
|
X |
|
|
|
Gross Phillip
200 CLARENDON STREET 52ND FLOOR BOSTON, MA 02116 |
|
X |
|
|
Signatures
|
||
/s/ Robert Atchinson | 5/26/2017 | |
** Signature of Reporting Person |
Date
|
|
s/ Adage Capital Partners, L.P.; By its general partner Adage Capital Partners GP, L.L.C.; By its managing member Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson | 5/26/2017 | |
** Signature of Reporting Person |
Date
|
|
s/ Adage Capital Partners GP, L.L.C.; By its managing member Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson | 5/26/2017 | |
** Signature of Reporting Person |
Date
|
|
/s/ Adage Capital Advisors, L.L.C.; By its managing member Robert Atchinson | 5/26/2017 | |
** Signature of Reporting Person |
Date
|
|
/s/ Phillip Gross | 5/26/2017 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Puma Biotechnology Chart |
1 Month Puma Biotechnology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions